Skip to main content


Corporate Governance

Board of Directors


Dan Burgess

Mr. Burgess has more than 20 years of executive level experience in the biotechnology and pharmaceutical industries. Mr. Burgess is currently a venture partner at SV Health Investors, and serves as the Acting President, Chief Executive Officer, and a director of Therini Bio, Inc., a private vascular biology company.In 2011, he was one of the founding members of Rempex, which was subsequently acquired by The Medicines Co. in 2013 for $140M upfront, with a total potential deal value of $474M. Prior to Rempex, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, which he joined in 2007. During his tenure as Chief Executive Officer, Mpex advanced its lead product Aeroquin from Phase 1 into Phase 3 clinical trials, raised substantial venture capital funding and ultimately achieved a successful exit in 2011 with its acquisition by Aptalis. The transaction with Aptalis was named by Scrip magazine as a finalist for “Deal of the Year”. Before joining Mpex, Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Hollis-Eden Pharmaceuticals, Inc., a publicly traded biotechnology company focused on biodefense, infectious disease and immune system disorders. Previously, he spent ten years at Gensia Sicor, Inc., which is a specialty pharmaceutical firmand was acquired by Teva Pharmaceutical Industries Limited, where he held a variety of executive level positions with responsibility for overall finance for the company as well as a number of different operating units. Mr. Burgess received his Economics from Stanford University and an MBA from Harvard Business School. Mr. Burgess was a member of the Board of Directors of Santarus, Inc. until its acquisition by Salix for $2.6B in 2013.

Bonnie Bassler, Ph.D.

Dr. Bassler currently serves in several roles at Princeton University, including Chair of the Department of Molecular Biology since 2013, associated faculty member of the Department of Chemistry since 2010, Investigator at the Howard Hughes Medical Institute since 2005, Professor in the Department of Molecular Biology since 1994, and associate faculty member of the Princeton Environmental Institute since 1996. Previously, Dr. Bassler served as the Director of the Council on Science and Technology at Princeton University from July 2008 to June 2013. Dr. Bassler has served as a board member of Royalty Pharma plc since June 2020, as a board member of Regeneron Pharmaceuticals, Inc. since 2016, and as a Trustee of the Alfred P. Sloan Foundation since 2014, and previously served as a board member of Sanofi from November 2014 to September 2016. Dr. Bassler served as a board member of the American Association for the Advancement of Science from January 2012 to December 2016. She was a member of the National Science Board from January 2010 until May 2016. Dr. Bassler has been elected to the National Academy of Sciences, the National Academy of Medicine, and the Royal Society, among other honorific organizations. She received a B.S. in biochemistry from the University of California-Davis and a Ph.D. in biochemistry from the John Hopkins University.

Carin Canale-Theakston

Ms. Canale-Theakston currently serves as Chief Executive Officer of Canale Communications Inc., a life sciences communications company that she founded in May 2010. Prior to founding Canale Communications, Ms. Canale-Theakston served as President of the life sciences division of Porter Novelli, an international public relations firm, from May 2005 until May 2010. Prior to Porter Novelli, Ms. Canale-Theakston was a Partner and Managing Director of Atkins + Associates, a life sciences communication firm, from February 2000 until it was acquired by Porter Novelli in May 2005. She has also served as a member of the CONNECT (previously San Diego Venture Group), board since January 2007, including Chair in 2011-2012. Since January 2007, Ms. Canale-Theakston has served as a member and vice chair of the board of directors of BIOCOM and is currently chair of the nominating-governance committee. Ms. Canale-Theakston also serves on the advisory board for Abintus Bio and Epitracker Inc. Ms. Canale-Theakston holds a B.A. in communications and marketing from the University of Tulsa.

James Merson, Ph.D.

James Merson, Ph.D., is the Chief Virology Officer at a stealth oncology biotechnology company. He is a member of the R&D Leadership Team, leading the viral vector platform. As the former Global Therapeutic Head of Infectious Diseases at Janssen, James lead R&D that resulted in approval of Cabenuva, line extensions of Symtuza & Juluca, 5 Ph3, 10 Ph2, and 8 Ph1 studies, 9 NMEs, and in-licensing of JNJ-0953 (antiviral drug conjugate for influenza PrEP) and JNJ- 3989 (siRNA for HBV for combination with HBV a therapeutic vaccine and anti-PD1 mAb).

James held more than 30 years of R&D experience in antivirals, vaccines and immuno-oncology at Pfizer, becoming SVP and CSO of Vaccine Immunotherapeutics Research Unit. As a member of the Vaccines leadership, he contributed to the approval of Prevnar 13 & 20 and ABRYSVO, and oversaw 4 Ph1/2 studies with oncology vaccines or oncolytic viruses combined with tremelimumab and sasanlimab, 2 Ph1 studies for ant-IgE vaccine and anti-nicotine vaccine. James was responsible for starting Pfizer vaccines in 2005 with the acquisition of PowderMed and Coley Pharmaceuticals, that resulted in the acquisition of Wyeth Pharmaceuticals. James was also responsible for Pfizer’s first build-to-buy partnership with Ignite Pharmaceuticals that generated a novel armed oncolytic vaccinia virus and was evaluated in combination with sasanlimab in a Ph1 study. As Therapeutic Head, Antivirals at Pfizer, he oversaw approval of Selzentry, 4 Ph2 studies, Pfizer’s first gene therapy program for HIV with Immusol, and the in-licensing of dalbavancin and anidulafungin.

He holds a Ph.D. in Microbiology and Immunology, Baylor College of Medicine, Houston Texas and a B.A. in Biology from Bellarmine College, Louisville, KY. James has held multiple SAB and Advisor positions, consulted for several Venture Capital companies, holds 5 patents and has 48 publications.

Chrysa Mineo

Ms. Mineo led corporate development at Receptos, Inc., from 2009 to 2015, where strategic partnering efforts for Phase 3 immunology candidate ozanimod resulted in the company’s acquisition by Celgene for $7.2 billion. During her tenure,she played a key role in the Receptos initial public offering (IPO) and established product and technology collaborations with AbbVie, Ono, Lilly and Janssen. Prior to Receptos, Ms. Mineo held roles of increasing business development responsibilityat Neurocrine Biosciences from 1997 to 2009, where she led or played a primary role in negotiating and closing more than 25 transactions, including worldwide or regional product candidate collaborations from Phase 1 to registration and product in-licensing transactions. Prior to Neurocrine, Ms. Mineo served in various capacities in research, marketing and business development for such companies as Amgen, DNAX Research Institute, Schering Plough and Baxter Biotech. Ms. Mineo holds a B.S. in Zoology from theUniversity of California, Davis and received her MBA from Duke University’s Fuqua School of Business. Additionally, Ms. Mineo is a Co-Founder of Alume Biosciences, a member of the Director’s Council at the Scripps Institution of Oceanography, and a member of the Board of Directors of the San Diego Natural History Museum.

Ted Schroeder

Mr. Schroeder is currently Chief Executive Officer and a director of Nabriva Pharmaceuticals, a role he has held subsequent to the 2018 acquisition of Zavante Therapeutics, a company that he co-founded and served as President, Chief Executive Officer and a member of the Board of Directors. Prior to that, he was one of Cadence Pharmaceutical’s co-founders and served as President, Chief Executive Officer and a member of the Board of Directors member since its inception in May 2004 until its acquisition by Mallinckrodt Pharmaceuticals for $1.4 billion in 2014. From August 2002 to February 2004, he served as Senior Vice President of North American Sales and Marketing of Elan Pharmaceuticals, Inc., a neuroscience-based pharmaceutical company. From February 2001 to August 2002, Mr. Schroeder served as General Manager of the Hospital Products Business Unit at Elan, a position he also held at Dura Pharmaceuticals, Inc., a specialty respiratory pharmaceutical and pulmonary drug delivery company, from May 1999 to November 2000 until its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb Company, a global pharmaceutical company. Mr. Schroeder is the former Chairman of Biocom, the California life sciences trade association. Additionally, Mr. Schroeder is the current Chairman of The Antimicrobials Working Group (AWG), a trade association focused on improving the prospects for innovation in antimicrobials. Mr. Schroeder is also a current director of Otonomy, Inc. Previously Mr. Schroeder served on the board of Collegium Pharmaceuticals until May 2021 and he also served on the boards of Cadence Pharmaceuticals, Incline Therapeutics, Hyperion Therapeutics and Trius Therapeutics until their respective acquisitions. Mr. Schroeder holds a B.S. in Management from Rutgers University.

Ryan Spencer

Ryan Spencer is Chief Executive Officer of Dynavax, and a member of its board of directors, where he leads the vaccine company’s mission to help protect the world against infectious diseases. He first joined Dynavax in 2005 and, during his fourteen-year ascent to CEO, served in various positions with increasing responsibility across commercial, finance, investor relations, and corporate strategy. As Senior Vice President of the commercial organization, Mr. Spencer led the successful commercial launch of the industry’s first and only two-dose hepatitis B vaccine – HEPLISAV-B® – in 2018. In December 2019, he was appointed CEO and, in the wake of the COVID-19 pandemic, led the supply of Dynavax’s CpG 1018® adjuvant for nearly 1 billion COVID-19 vaccine doses to vaccine developers around the world. Under Mr. Spencer’s tenure as CEO, the company has established HEPLISAV-B® as the leader of the adult hepatitis B vaccine market in the U.S., secured product approvals in the European Union and Great Britain, advanced three novel vaccine clinical candidates, and grown its employee base by more than 75 percent.

Prior to joining Dynavax, he served as Assistant Controller at QRS Corporation and as a member of the audit practice at Ernst & Young. Mr. Spencer is an active member of the Biotechnology Innovation Organization (BIO) and serves as a member of the board of directors for Dynavax. He earned a Bachelor of Arts in Business Economics from University of California, Santa Barbara.

Laura Tadvalkar, Ph.D.

Laura Tadvalkar is a Managing Director on the Venture Team at RA Capital Management. Laura works on new company creation and early-stage investments, and serves as a Board Director for Mariana Oncology, Be Biopharma, Expansion Therapeutics, Hemab Therapeutics, Hyku Biosciences, Typewriter Therapeutics, and Aliada Therapeutics. Laura has a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University. Prior to RA, Laura was a Principal at MP Healthcare Venture Management. Prior to MP, she was a Consultant at Clarion Healthcare.

Jeffrey Stein, Ph.D.

Dr. Stein has been President, CEO and Director of Cidara since January 2014. Previously he was CEO of Trius Therapeutics, Inc. from 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from the U.S. Food and Drug Administration in June 2014. Tedizolid is now marketed by Merck under the name Sivextro. Dr. Stein currently serves as a Director of Paratek Pharmaceuticals (NASDAQ: PRTK) and Ideaya Biosciences. He is also founding Chairman and President of the Antimicrobials Working Group, an industry leading 501(c)(6) organization. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm’s San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego.

Committee Compositions

  • The Audit Committee consists of Dan Burgess (chair), Chrysa Mineo, and Ted Schroeder.
  • The Compensation and Human Capital Committee consists of Ted Schroeder (chair), Carin Canale-Theakston, and Chrysa Mineo.
  • The Nominating and Corporate Governance Committee consists of Bonnie Bassler, Ph.D. (chair), Dan Burgess, and James Merson.